2019-12-24
Ensuring Public Medication Safety: Jiuzhitang Makes a Solemn Commitment
In the future, Jiuzhitang will remain committed to addressing public health needs by continuously monitoring the quality standards and traceability of authentic medicinal materials in its existing product line. We will actively engage in research aimed at evaluating the clinical value of traditional Chinese medicine and assessing renowned classic prescriptions, all while striving to enhance product quality. At the same time, we will relentlessly innovate and develop new products, delivering even better healthcare solutions to the public.
+2019-11-20
Jiuzhitang Maker's clinical trial application for a new stem-cell drug has been accepted.
This clinical trial application for Jiuzhitang Maker is the first submitted to the National Center for Drug Evaluation involving the use of imported stem cell products.
+2019-11-05
Dr. Epstein suggested that repeated intravenous injections of MSCs may help control the persistent abnormal inflammation following left ventricular assist device implantation, thereby improving patients' myocardial function. Stem cell therapy holds promise as an effective approach for treating cardiovascular diseases.
+2019-10-31
Jiuzhi Interview Room | I watched 100% of this ceremony! What impressed you the most?
What impressed you most about the National Day military parade?
+2019-10-30
Mr. Li Zhenguo, Chairman of Jiuzhitang, said that innovation is the only path forward for the development of traditional Chinese medicine enterprises.
+2019-10-25
Jiuzhitang Maker proudly earns the title of National High-Tech Enterprise.
High-tech enterprises are a specialized qualification system established by the national government to support and encourage the growth of high-tech companies, restructure industrial sectors, and enhance the nation's economic competitiveness—playing a critically important strategic role in China's economic development.
+